A5039409527- Advanced Radiotherapy Techniques
- Prostate Cancer Treatment and Research
- Management of metastatic bone disease
- Prostate Cancer Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Brain Metastases and Treatment
- Lung Cancer Research Studies
- Palliative Care and End-of-Life Issues
- Esophageal Cancer Research and Treatment
- Colorectal and Anal Carcinomas
- Bladder and Urothelial Cancer Treatments
- Colorectal Cancer Surgical Treatments
- Patient-Provider Communication in Healthcare
- Radiopharmaceutical Chemistry and Applications
- Diagnosis and treatment of tuberculosis
- Statistical Methods in Clinical Trials
- Cervical Cancer and HPV Research
- Retinal and Macular Surgery
- Spine and Intervertebral Disc Pathology
- Ethics in medical practice
- Orthopaedic implants and arthroplasty
- Urologic and reproductive health conditions
- CNS Lymphoma Diagnosis and Treatment
- Polyomavirus and related diseases
- Anesthesia and Pain Management
Kaiser Permanente
2023
Oregon Health & Science University
2021-2023
University of California, Los Angeles
2017-2021
University of California, San Francisco
2014-2017
Medical College of Wisconsin
2012
Abstract Background The aim of this study was to compare patient perceptions radiotherapy (RT) before and after treatment better inform future patients providers. Methods Seventy‐eight consecutive with rectal adenocarcinoma treated neo‐ or adjuvant chemoradiation, surgical resection, chemotherapy from 2009 2018 who were without recurrence included. Patients surveyed ≥6 months ileostomy reversal ≥3 chemotherapy. survey assessed patients' baseline knowledge fears RT, how their short‐ long‐term...
Abstract Background Radiation oncologists (ROs) play an important role in managing cancer pain; however, their opioid prescribing patterns remain poorly described. Methods The 2016 Medicare Physician Compare National Downloadable and the Part D Prescriber Data files were cross‐linked to identify RO‐written prescriptions. Results Of 4,627 identified ROs, 1,360 (29.3%) wrote >10 average number of prescriptions written was significantly ( P ≤ .05) associated with following RO...
211 Background: Low-volume de novo metastatic hormone-sensitive prostate cancer (mHSPC) has historically been treated with lifelong androgen deprivation therapy (ADT). Recently, however, the addition of several advanced therapeutic options – radiation (RT) to primary, hormonal agents such as abiraterone acetate/prednisone (AAP), and chemotherapy ADT have shown improve survival in low-volume mHSPC. The objective this study was compare cost-effectiveness treating mHSPC patients upfront RT+ADT,...